Findings

What do systematic reviews say?

22 questions · 27 findings · 12 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 8 · 29.6%GRADE not reported 0 · 0%Very low 7 · 25.9%Low 8 · 29.6%Moderate 4 · 14.8%High 0 · 0%

Vitamin K antagonists vs low molecular weight heparin

Major bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents

The review found no eligible studies for this question.

2 findings from 1 review

Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low molecular weight heparin vs vitamin K antagonist (VKA)

Major bleeding · patients with symptomatic VTE requiring long term treatment (3 months) for symptomatic VTE

LMWH may leads to lower incidence of major bleeding (treatment duration 3 months) compared with VKA (low certainty).

1 finding from 1 review

Vitamin K antagonists versus low‐molecular‐weight heparin for the long term treatment of symptomatic venous… 2017 · Cochrane Headline outcomes only
Peto OR 0.51 [0.32, 0.8]
16 studies · 3299 participants
Low